Oxidative stress represents one of the most fundamental and early pathogenic mechanisms in neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD)[@butterfield2023][@dias2023]. Defined as an imbalance between the production of reactive oxygen species (ROS) and the cellular antioxidant defense capacity, oxidative stress contributes to neuronal dysfunction and death through multiple pathways, including lipid peroxidation, protein oxidation, DNA damage, and mitochondrial dysfunction["@fischer2023"]. The brain is particularly vulnerable to oxidative damage due to its high metabolic rate, elevated oxygen consumption, and relatively limited antioxidant capacity compared to other organs["@cobley2023"].
The role of oxidative stress in neurodegeneration has evolved from being considered a secondary consequence of other pathological processes to a primary driver of disease initiation and progression["@gandhi2022"]. Evidence demonstrates that oxidative damage precedes the appearance of classic pathological hallmarks such as [amyloid-beta](/proteins/amyloid-beta) plaques, neurofibrillary tangles, or [alpha-synuclein](/proteins/alpha-synuclein) inclusions, suggesting that oxidative stress may be an early upstream event that initiates or accelerates downstream pathological cascades["@keller2024"].
The mitochondria represent the primary cellular source of ROS, generating superoxide anion (O₂•⁻) as a byproduct of normal oxidative phosphorylation[@lin2024]. Complex I (NADH dehydrogenase) and Complex III (ubiquinol-cytochrome c reductase) of the electron transport chain (ETC) are the main sites of superoxide production during normal respiration. Under physiological conditions, approximately 0.2-2% of oxygen consumed by mitochondria is partially reduced to form superoxide, which is then converted to hydrogen peroxide (H₂O₂) by superoxide dismutase (SOD).
In neurodegenerative diseases, mitochondrial dysfunction leads to increased ROS production through multiple mechanisms. Mutations in mitochondrial DNA (mtDNA) accumulate with age and are enhanced in AD and PD, leading to defective ETC components that produce more superoxide[@wallace2023]. Impaired complex activities (particularly Complex I in PD and Complex IV in AD) create electron leak and enhance ROS generation[@parker2023].
NADPH oxidases represent another major source of ROS in the brain, particularly in glial cells and neurons[@bedard2023][@sorce2024]. Originally discovered in phagocytic cells as a host defense mechanism, NOX enzymes are now known to be expressed in neurons and glia where they produce ROS in response to various stimuli. The NOX2 isoform is highly expressed in microglia and is activated by amyloid-beta, leading to ROS production that contributes to neuroinflammation and neuronal damage in AD.
Brain metal ion dyshomeostasis, particularly of iron, copper, and zinc, contributes significantly to oxidative stress in neurodegeneration[@crichton2024]. Transition metals can catalyze the production of highly reactive hydroxyl radicals (•OH) through the Fenton reaction, where reduced metals (Fe²⁺ or Cu⁺) react with hydrogen peroxide to produce •OH and the oxidized metal form[@halliwell2024].
In Alzheimer's disease, elevated iron and copper levels colocalize with amyloid-beta plaques. Iron accumulation in the substantia nigra is a characteristic finding in Parkinson's disease and is believed to contribute to the selective vulnerability of dopaminergic neurons[@zecca2024].
Cells possess multiple enzymatic antioxidant systems to neutralize ROS and maintain redox homeostasis. Superoxide dismutase (SOD) converts superoxide to hydrogen peroxide, with three isoforms: cytosolic Cu/Zn-SOD (SOD1), mitochondrial Mn-SOD (SOD2), and extracellular SOD (SOD3)[@valentine2024]. Mutations in SOD1 are responsible for approximately 20% of familial ALS cases[@rosen2023].
Catalase and glutathione peroxidases (GPx) convert hydrogen peroxide to water. The glutathione system is crucial for neuronal antioxidant defense, and GSH levels are reduced in AD, PD, and other neurodegenerative conditions[@aoyama2024].
Vitamin E (alpha-tocopherol) is the most important lipid-soluble antioxidant, protecting cell membranes from lipid peroxidation. Vitamin C (ascorbic acid) is the major water-soluble antioxidant in the brain.
Coenzyme Q10 (ubiquinone) is a mitochondrial antioxidant that also functions in electron transport[@giacometti2024]. CoQ10 supplementation has shown some promise in clinical trials for neurodegenerative diseases[@shults2023].
The recognition of oxidative stress as a key pathogenic mechanism has driven the development of antioxidant-based therapeutic strategies. Direct antioxidants such as vitamin E, vitamin C, and CoQ10 have been tested in clinical trials for AD and PD with mixed results. More sophisticated approaches target specific sources of ROS rather than global antioxidant supplementation.
The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) is the master regulator of antioxidant response genes[@johnson2024][@kensler2023]. Under basal conditions, Nrf2 is sequestered in the cytoplasm by Keap1. Upon oxidative stress, Nrf2 translocates to the nucleus and activates expression of antioxidant and cytoprotective genes.
Nrf2 activators such as dimethyl fumarate (approved for multiple sclerosis) are being tested in neurodegenerative diseases.
Oxidative stress is a central mechanism in the pathogenesis of neurodegenerative diseases, acting both as an early trigger of pathology and as a contributor to disease progression through multiple downstream effects.
The following diagram shows the key molecular relationships involving Oxidative Stress in Neurodegeneration discovered through SciDEX knowledge graph analysis: